These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15352027)

  • 1. Histone deacetylase inhibitors: understanding a new wave of anticancer agents.
    Villar-Garea A; Esteller M
    Int J Cancer; 2004 Nov; 112(2):171-8. PubMed ID: 15352027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CpG island methylation and histone modifications: biology and clinical significance.
    Esteller M
    Ernst Schering Res Found Workshop; 2006; (57):115-26. PubMed ID: 16568952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer activities of histone deacetylase inhibitors.
    Bolden JE; Peart MJ; Johnstone RW
    Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
    Santini V; Gozzini A; Ferrari G
    Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Histone-deacetylases inhibitors: from TSA to SAHA].
    Peixoto P; Lansiaux A
    Bull Cancer; 2006 Jan; 93(1):27-36. PubMed ID: 16455503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
    Yoshida M; Shimazu T; Matsuyama A
    Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rational development of histone deacetylase inhibitors as anticancer agents: a review.
    Acharya MR; Sparreboom A; Venitz J; Figg WD
    Mol Pharmacol; 2005 Oct; 68(4):917-32. PubMed ID: 15955865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors: anticancer compounds.
    Smith KT; Workman JL
    Int J Biochem Cell Biol; 2009 Jan; 41(1):21-5. PubMed ID: 18845268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting histone deacetylase in cancer therapy.
    Lin HY; Chen CS; Lin SP; Weng JR; Chen CS
    Med Res Rev; 2006 Jul; 26(4):397-413. PubMed ID: 16450343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors in cancer therapy. A review.
    Hrabeta J; Stiborova M; Adam V; Kizek R; Eckschlager T
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Jun; 158(2):161-9. PubMed ID: 24263215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histone deacetylase inhibitors--a new tool to treat cancer.
    Somech R; Izraeli S; J Simon A
    Cancer Treat Rev; 2004 Aug; 30(5):461-72. PubMed ID: 15245778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors: a review of their clinical status as antineoplastic agents.
    Garcia-Manero G; Issa JP
    Cancer Invest; 2005; 23(7):635-42. PubMed ID: 16305991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
    Fang JY
    J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.